One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin
-
Published:2021-10
Issue:
Volume:908
Page:174366
-
ISSN:0014-2999
-
Container-title:European Journal of Pharmacology
-
language:en
-
Short-container-title:European Journal of Pharmacology
Author:
Zhu Haiying,
Rao Zijian,
Yuan SichenORCID,
You Jieqiong,
Hong Chenggang,
He Qiaojun,
Yang Bo,
Du Chengyong,
Cao Ji
Reference39 articles.
1. Chk1 as a new therapeutic target in triple-negative breast cancer;Albiges;Breast,2014
2. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis;Bareche;Ann. Oncol.,2018
3. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy;Bartucci;Cell Death Differ.,2012
4. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry;Bauer;Cancer,2007
5. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies;Chou;Pharmacol. Rev.,2006
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献